Press coverage about Epizyme (NASDAQ:EPZM) has trended somewhat positive this week, according to Accern. The research firm ranks the sentiment of media coverage by monitoring more than twenty million blog and news sources in real time. Accern ranks coverage of public companies on a scale of negative one to one, with scores closest to one being the most favorable. Epizyme earned a daily sentiment score of 0.14 on Accern’s scale. Accern also assigned news headlines about the biopharmaceutical company an impact score of 45.0655262238686 out of 100, meaning that recent media coverage is somewhat unlikely to have an effect on the stock’s share price in the near term.
These are some of the news headlines that may have impacted Accern Sentiment Analysis’s scoring:
- MF Rank in Focus For CONE Midstream Partners LP (NYSE:CNNX) (eslforkids.net)
- Market Investors Buy Unusual Volume of McDonald’s Corporation Bearish Bets (fishinghd.com)
- McDonald’s Corporation (MCD) Shares Sold by Parthenon LLC (iphonefresh.com)
- Epizyme, Inc. (EPZM) while Akcea Therapeutics, Inc. (AKCA) finishes with a flow of 17.58% – Stocks Gallery (stocksgallery.com)
- Epizyme Inc (EPZM) Chaiken Money Flow Indicates Solid Buying Pressure – Financial News Review (finnewsreview.com)
EPZM has been the subject of several analyst reports. Zacks Investment Research raised Epizyme from a “hold” rating to a “buy” rating and set a $18.00 price objective for the company in a research note on Tuesday, May 16th. Wedbush reaffirmed an “outperform” rating and issued a $24.00 price objective on shares of Epizyme in a research note on Thursday, May 18th. HC Wainwright reaffirmed a “buy” rating on shares of Epizyme in a research note on Friday, May 19th. ValuEngine lowered Epizyme from a “hold” rating to a “sell” rating in a research note on Saturday, June 3rd. Finally, Oppenheimer Holdings, Inc. set a $26.00 price objective on Epizyme and gave the company a “buy” rating in a research note on Monday, June 5th. Two investment analysts have rated the stock with a hold rating and eleven have assigned a buy rating to the stock. The company presently has an average rating of “Buy” and an average price target of $23.38.
Shares of Epizyme (NASDAQ EPZM) opened at 18.25 on Tuesday. Epizyme has a one year low of $7.51 and a one year high of $18.80. The stock’s market capitalization is $1.07 billion. The stock has a 50 day moving average price of $14.56 and a 200 day moving average price of $15.07.
Epizyme (NASDAQ:EPZM) last released its quarterly earnings data on Friday, August 4th. The biopharmaceutical company reported ($0.48) EPS for the quarter, beating analysts’ consensus estimates of ($0.56) by $0.08. Epizyme had a negative return on equity of 63.10% and a negative net margin of 1,376.33%. The firm had revenue of $10 million for the quarter, compared to analysts’ expectations of $3.95 million. During the same period in the prior year, the firm posted ($0.49) earnings per share. The firm’s quarterly revenue was up 2027.7% on a year-over-year basis. Equities analysts forecast that Epizyme will post ($2.39) earnings per share for the current year.
In related news, CFO Andrew E. Singer sold 3,024 shares of the company’s stock in a transaction that occurred on Friday, June 30th. The stock was sold at an average price of $15.50, for a total value of $46,872.00. Following the transaction, the chief financial officer now directly owns 40,529 shares in the company, valued at $628,199.50. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, insider Peter Tai-Ching Ho sold 15,000 shares of the company’s stock in a transaction that occurred on Monday, June 26th. The shares were sold at an average price of $14.87, for a total value of $223,050.00. Following the completion of the transaction, the insider now owns 22,228 shares in the company, valued at $330,530.36. The disclosure for this sale can be found here. Insiders sold 48,024 shares of company stock worth $706,722 over the last quarter. 25.20% of the stock is currently owned by insiders.
ILLEGAL ACTIVITY WARNING: “Epizyme (EPZM) Receiving Somewhat Positive Media Coverage, Analysis Finds” was first reported by Markets Daily and is the property of of Markets Daily. If you are accessing this piece of content on another website, it was stolen and reposted in violation of U.S. & international copyright law. The original version of this piece of content can be viewed at https://www.themarketsdaily.com/2017/09/12/epizyme-epzm-receiving-somewhat-positive-media-coverage-analysis-finds.html.
Epizyme Company Profile
Epizyme, Inc is a clinical-stage biopharmaceutical company. The Company discovers, develops and plans to commercialize epigenetic therapies for cancer patients. The Company is engaged in the discovery and development of novel epigenetic therapies for cancer patients. The Company develops small molecule inhibitors of a class of enzymes known as histone methyltransferases (HMTs).
Receive News & Ratings for Epizyme Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Epizyme Inc. and related companies with MarketBeat.com's FREE daily email newsletter.